Status:
NOT_YET_RECRUITING
Catestatin as a Novel Biomarker for Cardiovascular and Microvascular Involvement in Systemic Sclerosis
Lead Sponsor:
Assiut University
Conditions:
Systemic Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
This study investigates the relationship between serum catestatin levels and systemic sclerosis (SSc), with a focus on cardiovascular involvement and microvascular alterations, to determine catestatin...
Detailed Description
Systemic sclerosis is a chronic autoimmune disease characterized by fibrosis, autoimmunity, and vasculopathy, with cardiovascular complications accounting for a significant proportion of morbidity and...
Eligibility Criteria
Inclusion
- Patients diagnosed with systemic sclerosis according to 2013 ACR-EULAR classification criteria.
- Age \>18 years.
Exclusion
- Other autoimmune disorders.
- Cardiovascular conditions not linked to systemic sclerosis.
- Comorbidities affecting catestatin metabolism (e.g., diabetes, chronic kidney disease, obesity).
Key Trial Info
Start Date :
November 1 2026
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT07209644
Start Date
November 1 2026
End Date
December 1 2027
Last Update
October 7 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.